OpenNCT05888233View on ClinicalTrials.gov ↗⚑ Report an issue with this listing

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Allopurinol Improves Diastolic Function in African Americans With Resistant Hypertension (RESIST)

Open to underrepresented populationsRace/ethnicity-specific condition

Phase

PHASE2

Enrollment

Not reported

Age range

— to —

Sex

ALL

Summary

African American adults in the United States have the highest prevalence of high blood pressure and heart failure in the world. Those with treatment-resistant hypertension have higher levels of the enzyme xanthine oxidase than white patients. This single-arm Phase 2 study evaluates whether allopurinol improves heart (diastolic) function in African Americans with resistant hypertension. (Dates, sites, and site contacts were not available in the source consulted and are pending a full ClinicalTrials.gov API sync.)

Conditions studied

Heart Failure Preserved Ejection FractionResistant Hypertension

Allopurinol Improves Heart Function in African Americans With Resistant Hypertension

Summary

Conditions studied

Sponsors